Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Kala Pharmaceuticals (KALA) Misses Q3 EPS by 6c, Revenues Beat
November 5, 2020 8:43 AM ESTKala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($0.50), $0.06 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $2.22 million versus the consensus estimate of $2.01 million.
We are pleased with our third quarter results and the fourth quarter of 2020... More
